簡介Profile

醫工出身・顧問訓練・AI 轉型Biomedical engineering · Consulting · AI transformation

三個能力支柱Three capability pillars

  • A
    AI 策略與轉型AI Strategy & Transformation

    把公司策略接到真正值得投資的幾個 AI 場景,算清楚效益,定一個客戶願意簽的 KPI。Connect business strategy to the few AI use cases worth funding, with a business case and a KPI the client will sign.

  • B
    企業 AI 導入與產品化Enterprise AI Delivery & Productisation

    把 AI 從試點做到上線、真的有人在用:方案設計、地端部署、驗收關卡、定價。Take AI from pilot to production and adoption: solution design, on-premises deployment, acceptance gates and pricing.

  • C
    AI 治理、資安與風險AI Governance, Cybersecurity & Risk

    讓 AI 跟資料過得了監理這一關:AI 治理、Zero Trust、成熟度評估、稽核。Make AI and data safe enough for a regulator: AI governance, Zero Trust, maturity assessment and assurance.

產業Industry金融Financial services銀行、證券、壽險:Zero Trust、海外合規、理賠 AIBanks, securities, life insurance: Zero Trust, overseas compliance, claims AI看金融案子Finance engagements →
產業Industry醫療Healthcare醫院、健檢集團、衛福部、健保署,還有自己創業的臨床軟體Hospitals, health-check groups, MOHW and NHIA, and my own clinical-software startup看醫療與醫材Healthcare & medtech →

四個可以驗證的數字Four proof points

US$4M
Deloitte 時期由我領導的新服務計畫,在規範完成後,於 2023–24 年帶進來的新營收,包含台灣五大銀行的多年合約。成果跟團隊共享。New revenue from a new service programme I led at Deloitte, brought in during 2023–24 once the guidelines were in place, including multi-year contracts with Taiwan's five largest banks. A result shared with the team.
US$2M+
iKala 12 個月建立的企業 AI pipeline,約 15 個客戶。這是 pipeline 不是營收;其中 6 家(US$1.5M+)由我帶隊、跟團隊一起簽下。Enterprise AI pipeline built at iKala in 12 months, about 15 accounts. Pipeline, not revenue; 6 of them (US$1.5M+) were closed by the team I led.
4 + 2
用 Encorphin 臨床軟體的醫院跟診所,2017–19。我是共同創辦人暨執行長。Hospitals and clinics running Encorphin's clinical software, 2017–19. I was co-founder and CEO.
共同主筆Co-lead author
金管會金融業零信任架構參考指引(2024),以及數位身分驗證指引(2023)。兩份都是多位作者共同撰寫。Taiwan FSC Zero Trust Architecture Guidelines for the financial sector (2024) and the Digital Identity Verification Guidelines (2023). Both have several co-authors.

關於我About

  1. 01醫工出身Biomedical engineering

    研究所在台大做組織工程,主修基因轉殖(用 CRISPR/Cas9 做基因 knock-in、knock-out),再用機器學習分析 CT、MRI 影像,訓練模型做單一幹細胞追蹤,在雙光子顯微鏡下追蹤活體細胞。同時跟朋友創業,把一套臨床軟體做進 4 家醫院,拿到一家 Fortune Global 500 投資人跟政府補助,約 US$5 萬的種子資金。At National Taiwan University I worked on tissue engineering and gene editing (CRISPR/Cas9 knock-in and knock-out), and used machine learning on CT and MRI images and for single stem-cell tracing, following living cells under a two-photon microscope. In parallel I co-founded a startup with friends and took its clinical software into four hospitals, with about US$50K of seed funding from a Fortune Global 500 investor and government grants.

  2. 02顧問訓練Consulting

    短暫做過獵頭之後,在 Deloitte 待了四年,從初階顧問做起,提前升遷兩次:資安策略、資安與個資管理制度導入、Zero Trust、資安治理成熟度、海外金融合規,跑過台灣、泰國、新加坡、香港跟美國(舊金山、矽谷、洛杉磯、芝加哥)。After a short stint in executive search I spent four years at Deloitte, starting as a consultant and promoted twice ahead of schedule: cyber strategy, security and privacy management systems, Zero Trust, cyber-governance maturity and overseas financial compliance, across Taiwan, Thailand, Singapore, Hong Kong and the US (San Francisco, Silicon Valley, Los Angeles and Chicago).

  3. 03AI 轉型AI transformation

    最近一份工作在 iKala 帶企業 AI 導入:從篩選值得做的場景、做資料不出門的一體機,到簽約跟上線後的採用追蹤,都是跟團隊一起打下來的。2026 年從 INSEAD 畢業,中間經徵選到 Kellogg 交換;這段時間住過新加坡、法國跟芝加哥,現在住新加坡。Most recently I led enterprise AI delivery at iKala with my team: choosing the use cases worth funding, building a one-box that keeps data on-premises, and carrying deals through contract and post-launch adoption. I graduated from INSEAD in 2026, with a selective exchange term at Kellogg, having lived in Singapore, France and Chicago. I am now based in Singapore.

我在找的角色,以及新創投資What I'm looking for, and startup investing

希望能對「AI 有沒有真的被用起來」負責的角色:AI 轉型、AI 策略或成果交付,產業是金融或醫療,地點在新加坡、台北或香港。這兩個產業都受監理,AI 能不能上線常常是治理說了算,我做過的事剛好都落在這裡。A role that owns whether AI actually gets used: AI transformation, AI strategy or outcome delivery, in financial services or healthcare, based in Singapore, Taipei or Hong Kong. In regulated industries governance decides whether AI ships, and that is where my consulting, governance and biomedical work meet.

我也關注新創投資:曾在新加坡 AngelSchool 的創投團隊實習三個月,看了 10 多個亞洲早期的軟體跟醫材案子,寫投資或不投的建議。I also follow startup investing: I spent three months as a venture capital intern at AngelSchool in Singapore, screening 10+ early-stage software and medtech deals across Asia and writing invest-or-pass recommendations.

精選案例Selected cases

我做的事,是把我們答應客戶的數字,變成客戶自己系統裡跑得出來的數字。下面三個例子:I turn the number we promised into the number that shows up in the client's own system. Three examples:

iKala · Dec 2024 — Jan 2026 · BA

企業 AI:從試點走到簽約Enterprise AI, from pilot to signed contracts

US$2M+pipelinepipeline
背景Context
台灣的 AI SaaS 公司 iKala,我是 AI 服務與產品資深經理,2025 年 5 月起在執行長室。iKala, an AI SaaS company in Taiwan. I was Senior Manager, AI Services and Product, in the CEO Office from May 2025.
挑戰Challenge
企業都想用生成式 AI,但卡在試點:場景沒共識、敏感資料不能出門、上線之後沒人對結果負責。Enterprise buyers wanted generative AI but stalled at pilots: no agreed use case, data that could not leave the building, and nobody owning the result after go-live.
我的角色My role
企業 AI 產品線的共同負責人,也負責企業客戶開發;帶 1 位直屬同事,跟產品、工程、FDE 跟硬體夥伴(NVIDIA 合作夥伴麗臺)一起做,投資決策報給營運長跟執行長。Co-owner of the enterprise AI portfolio and lead for enterprise business development; one direct report, working with product, engineering, forward-deployed engineers and the hardware partner (Leadtek, an NVIDIA partner). Investment calls went to the COO and CEO.
我做的決定Decisions I owned
用 ROI 跟可行性篩場景,過不了門檻的就砍;收斂成三條產品線,排好功能清單跟開發順序;為受監理的客戶做資料不出門的 Nexus 一體機;目標客戶方法從零建立,每個產業設 ROI 門檻,先帶團隊打電話驗證;硬體加軟體的報價用我建的成本與毛利模型;用「先 PoC」跟「簽約金+訂閱」降低下一張合約的門檻;也跟一個國防客戶說,你們不需要 AI。Screened use cases on ROI and feasibility and cut those under the return threshold; narrowed to three product lines with a feature list and build order for each; built Nexus, an on-premises one-box for regulated buyers whose data cannot leave; built the target-account method from zero with an ROI threshold per segment, and ran outbound with the team to validate it; priced hardware-plus-software bundles on a cost and margin model I built; used PoC-first and signing-fee-plus-subscription deals to lower the barrier to the next contract; told one defence client it did not need AI.
成果Outcome
12 個月建立約 15 個客戶、US$2M+ 的 pipeline;其中 6 家由我帶隊、跟團隊一起簽下(US$1.5M+),包含 US$500K 跟 US$600K 兩張主力合約。Nexus 約 6 個月做出來,2025 年 9 月展出。A US$2M+ pipeline across about 15 accounts in 12 months; the team I led closed 6 of them (US$1.5M+), including two anchor deals of US$500K and US$600K. Nexus shipped in about six months and launched in September 2025.
做法與佐證Approach & evidence

圖都是我重畫的;客戶名稱不公開。Diagrams are redrawn by me; client names are withheld.

Deloitte · 2023 — 2024 · CA

台灣金融業第一個 Zero Trust 計畫Taiwan's first Zero Trust programme in banking

US$4M新簽營收signed revenue
背景Context
台灣的銀行要往 Zero Trust 走,但當時還沒有國家層級的指引。Deloitte Taiwan 資安與策略風險部門。Taiwan's banks were moving to Zero Trust before any national guideline existed. Deloitte Taiwan, Cyber and Strategic Risk.
挑戰Challenge
「做到什麼程度才算完成」沒有人定義過,案子很難定範圍、報價跟驗收。Nobody had defined what "done" meant, so projects were hard to scope, price or accept.
我的角色My role
從第一個諮詢案帶到多年合約(經理升資深經理),團隊是我帶的 6 人跨國小組;金管會 2024 零信任指引的共同主筆。Led the programme from the first advisory engagement to multi-year accounts (Manager, then Senior Manager), with the cross-border team of six I led; co-lead author of the FSC Zero Trust guidelines (2024).
我做的決定Decisions I owned
開工前先跟客戶講定可以驗證的成果;跟主管機關一起寫指引,讓它變成整個產業的基準;把評估、建置、維運包成一個多年方案,不分開賣;路線圖排到 2028 年。Agreed a verifiable outcome with the client before the build; wrote the guidelines with the regulator so they became the sector baseline; bundled assessment, build and operations into one multi-year offer; sequenced the roadmap to 2028.
成果Outcome
US$4M 新簽營收,台灣五大銀行的多年合約,路線圖確定到 2028 年,另外帶出 US$2M 的後續建置工作。這是團隊成果。US$4M in new, signed revenue from multi-year accounts with Taiwan's five largest banks, roadmaps committed to 2028, and US$2M of follow-on implementation work. A team result.
做法與佐證Approach & evidence

架構圖是依公開標準重畫的示意圖,不是客戶文件。Architecture diagrams are illustrative redraws based on public standards, not client documents.

Encorphin · 2017 — 2019 · BA

把門診問診做成臨床軟體Clinical software for the outpatient interview

−67%候診時間waiting time
背景Context
台灣的門診;Encorphin 是我共同創辦的醫療軟體(SaMD)新創,2017 年 6 月到 2019 年 2 月。Outpatient clinics in Taiwan. Encorphin was the Software-as-a-Medical-Device startup I co-founded, June 2017 to February 2019.
挑戰Challenge
門診一直拖,因為醫師對每個病人都要重問一次同樣的病史。Clinics ran late because doctors asked every patient the same history questions again.
我的角色My role
共同創辦人暨執行長;帶 3 人開發團隊,訪談、需求跟每一站的上線我負責。Co-founder and CEO; led a three-person dev team and owned discovery, requirements and each site rollout.
我做的決定Decisions I owned
寫程式之前先訪 100 多位醫師、跑 40 多家診所,再跟 20 多位臨床人員定需求;先做候診問卷、一頁摘要跟排程流程;醫師確認過才寫進病歷;一家一家上線,每個版本都在真實門診裡驗證。Interviewed 100+ doctors across 40+ clinics before coding, then defined requirements with 20+ clinicians; started with pre-visit intake, a one-page summary and scheduling workflow; nothing enters the record until the doctor confirms; rolled out site by site, validating every release in live outpatient flow.
成果Outcome
4 家醫院、2 家診所上線;病人候診時間少了 67%,每次看診約少等 37 分鐘。種子資金約 US$5 萬,來自一家 Fortune Global 500 投資人跟政府補助。Live in four hospitals and two clinics; patient waiting time down 67%, about 37 minutes per visit. About US$50K of seed funding from a Fortune Global 500 investor and government grants.
做法與佐證Approach & evidence
全部 16 個案子,可以照產業、能力、類型篩選All 16 engagements, filterable by industry, pillar and type →

能力與方法Capabilities & methods

方法都放在三個支柱底下。點進去是完整的框架、互動圖跟我實際用過的例子。Every method sits under one of the three pillars. Each link opens the full framework, the interactive diagrams and where I used it.

AAI 策略與轉型AI Strategy & Transformation

  • 問題拆解:MECE 跟 issue treeProblem structuring: MECE and issue trees

    一頭把問題拆開,一頭從結果往回推,五個問題把兩端接起來。Take the problem apart from one end, work backwards from the result at the other; five questions join them.

  • 場景排序跟 ROI 邏輯Use-case prioritisation and ROI logic

    每個模組都打分:Net Gain、Investment Cost、ROI%,公式寫清楚。Every module scored on Net Gain, Investment Cost and ROI%, with the formula shown.

  • 一張 KPI 卡KPI definition on one card

    baseline、target、owner、護欄,還有十個常見的設計陷阱。Baseline, target, owner and guardrails, plus ten common design traps.

  • 成果追蹤跟價值兌現Outcome measurement and value realisation

    每週看一次:數字離承諾還差多少、人有沒有真的在用、下一步誰負責。Read weekly: how far the number is from the promise, whether people use it, who owns the next step.

B企業 AI 導入與產品化Enterprise AI Delivery & Productisation

  • 從 proposal、SOW 到驗收From proposal and SOW to acceptance

    把成果寫進合約,每一步一個關卡,沒過就停。The outcome written into the contract, one gate per step, and a stop when a gate fails.

  • 主權 AI:Nexus 一體機Sovereign AI: the Nexus one-box

    私有 LLM、RAG、agent 工作流放在一台機器裡,資料不出門;兩個人進場的八個步驟。Private LLM, RAG and agentic workflows in one on-premises box; the eight on-site steps for a two-person team.

  • 流程重新設計跟整合Workflow redesign and integration

    例如壽險理賠:OCR、欄位抽取、規則、人工覆核怎麼接成一條線。For example, life-insurance claims: how OCR, field extraction, rules and human review join into one flow.

  • 成果節奏:AIOM 示範Outcome cadence: the AIOM demo ↗

    可以實際操作的成果儀表板,用的是虛構的示範資料。A working outcome cockpit, running on synthetic demo data.

CAI 治理、資安與風險AI Governance, Cybersecurity & Risk

  • AI 治理跟風險分級AI governance and risk tiering

    以 ISO/IEC 42001 為骨架:透明、問責、公平、安全與隱私、持續改進五個原則,落到 Annex A 的控制,再接上 23894 風險評分跟 EU AI Act。Built on ISO/IEC 42001: five principles (transparency, accountability, fairness, security and privacy, continuous improvement) turned into Annex A controls, with ISO/IEC 23894 risk scoring and the EU AI Act mapped on top.

  • 資安框架:成熟度、Zero Trust、NIST CSF 2.0Cyber frameworks: maturity, Zero Trust, NIST CSF 2.0

    把一套框架拆成一年四個關卡,一階一階爬。A framework broken into four gates a year, climbed one rung at a time.

  • 受監理產業的法遵與稽核Regulatory and assurance work

    NYDFS 500、MAS TRM、HKMA、金管會;醫療的 ISO 27799。NYDFS 500, MAS TRM, HKMA and FSC; ISO 27799 in healthcare.

我怎麼讓價值兌現How I make value show up

  1. 定數字Define the number先寫 KPI 卡:baseline、target、誰負責。Write the KPI card first: baseline, target, owner.
  2. 寫進合約Put it in the contractSOW 裡每一步一個關卡。One gate per step in the SOW.
  3. 每週追Track it weekly數字、採用率、上報,一頁看完。Number, adoption and escalations on one page.
  4. 證明再擴大Prove, then scale用客戶系統的證據談續約。Renew on evidence from the client's own system.

新職務的前 60 天(我的做法)First 60 days in a new AI mandate (my approach)

  1. 第 1–15 天 · 診斷Days 1–15 · Diagnose對齊要的商業成果,了解營運現況,盤點資料、技術跟風險限制,畫出關係人,把 baseline 量出來。Align on business outcomes, learn the operating context, assess data, technology and risk constraints, map stakeholders and set baseline metrics.
  2. 第 16–30 天 · 排序與設計Days 16–30 · Prioritise and design選出價值最高的場景,定目標營運模式跟效益試算,講清楚治理跟交付誰負責,講定成功怎麼量。Select high-value use cases, define the target operating model and business cases, settle governance and delivery ownership, and agree success measures.
  3. 第 31–60 天 · 動起來、證明價值、滾動調整Days 31–60 · Mobilise, prove, adjust on a rolling basis啟動一個排好優先順序的項目或受控試點,開始追採用跟價值;照實際的數字滾動調整範圍跟資源,解掉關鍵相依,講定擴大的路線圖。Launch a prioritised initiative or controlled pilot and start tracking adoption and value; adjust scope and resources on a rolling basis as the numbers come in, resolve critical dependencies and agree the scale-up roadmap.

這是我會怎麼做,不是某一份工作的實際紀錄。金融業會先處理監理跟資料分級,醫療業會先處理病人資料跟臨床流程。This is how I would approach it, not a record of a past job. In financial services I would start with regulatory and data-classification constraints; in healthcare, with patient data and clinical workflow.

經驗怎麼對應到角色How my experience maps to the role →

經歷My story

一條線:先學怎麼做出東西,再學怎麼讓它被信任,然後學怎麼讓它被用起來。One thread: first learn to build it, then learn to make it trusted, then learn to make it used.

  1. 2025 — 2026
    INSEAD MBA · Singapore / Fontainebleau
    Steven Yang in graduation gown, holding his INSEAD diploma folder
    INSEAD MBA 畢業,2026。INSEAD MBA graduation, 2026.

    2025 年 8 月到 2026 年 7 月,選修 Restructuring、Corporate Turnaround、流程再造,以及以醫療為主軸的 AI 策略、營運、科技與創新策略。August 2025 to July 2026, with electives in Restructuring, Corporate Turnaround, process re-engineering, and AI strategy, operations and technology and innovation strategy anchored in healthcare.

    RestructuringTurnaroundProcess re-engineeringAI strategyHealthcare
  2. 2026
    交換學生(經徵選)Exchange (selected) · Kellogg School of Management · Chicago
    Name card reading Steven Y., Northwestern Kellogg, next to a laptop with an INSEAD sticker
    Kellogg 教室裡的名牌,筆電上貼著 INSEAD 貼紙。2026 年春季。My Kellogg name card, next to a laptop with an INSEAD sticker. Spring 2026.

    經過學校徵選,2026 年 3 到 5 月到 Kellogg(芝加哥)交換,修生醫工程行銷、AI in Finance 跟 AI Strategy。Selected through INSEAD's exchange application for a term at Kellogg (Chicago area), March to May 2026: biomedical engineering marketing, AI in Finance and AI Strategy.

    AI in FinanceAI StrategyMedtech marketing
  3. 2024 — 2026
    資深經理,AI 服務與產品Senior Manager, AI Services and Product · iKala · Taipei / Singapore
    Steven Yang speaking on a panel at a forum on enterprise AI agents
    在數位發展部數位產業署主辦的國際論壇上,談企業 AI Agent 的應用。On a panel about enterprise AI agents, at an international forum hosted by Taiwan's Administration for Digital Industries (moda).

    2024 年 12 月到 2026 年 1 月,2025 年 5 月起在執行長室。企業 AI 產品線從 0 做到 3 條、12 個月 US$2M+ pipeline、6 家由我帶隊簽下;跟麗臺、NVIDIA 把 Nexus 一體機推上市;從零建立集團的營運節奏:轉型計分卡、月度經營會議、跟執行長報告的落差追蹤;也參與新加坡辦公室的設立。December 2024 to January 2026, CEO Office from May 2025. Took the enterprise AI portfolio from zero to three product lines, a US$2M+ pipeline in twelve months with six accounts closed by the team I led; took the Nexus one-box to market with Leadtek and NVIDIA; built the group operating cadence from scratch (transformation scorecard, monthly business review, gap-to-goal reporting to the CEO); helped set up the Singapore office.

    NexusRAGISO 42001GTM
  4. 2021 — 2024
    資深經理,資安與策略風險Senior Manager, Cyber and Strategic Risk · Deloitte Taiwan
    Steven Yang presenting in front of a projected slide at a Deloitte session
    在 Deloitte 擔任經理時上台分享。Presenting during my Manager years at Deloitte.

    2021 年 1 月進去當顧問,提前兩次升遷,3.5 年升到資深經理;帶 6 人跨國團隊做了 70 多個案子,同時最多 11 個;約七成營收來自回頭客戶。Zero Trust 做到 US$4M 新簽營收;美國分行 10 多次 AML/KYC 跟 IT 控制審查;港星泰 20 多套治理框架;金管會零信任指引跟數位身分驗證指引的共同主筆;參與撰寫台灣第一部數位長照服務法(2021),負責醫療的部分;6 個以上醫療案子。Joined as a consultant in January 2021 and was promoted twice ahead of the standard timeline, reaching Senior Manager in 3.5 years; led a cross-border team of six through 70+ engagements, up to eleven at once, with about 70% of revenue from repeat clients. Zero Trust grew to US$4M in new, signed revenue; 10+ AML/KYC and IT control reviews for US branches; 20+ governance frameworks in Hong Kong, Singapore and Thailand; co-lead author of the FSC Zero Trust guidelines and the Digital Identity Verification guidelines; co-authored Taiwan's first Digital Long-Term Care Services Act (2021), responsible for the healthcare sections; 6+ healthcare engagements.

    Zero TrustISO 27001AML/KYCNYDFS 500
  5. 2019 — 2020
    獵頭,以及醫療市場專案Executive search, and healthcare market projects

    研究所畢業後短暫做過獵頭。同一段時間跟著一家跨國醫材代理商的團隊,幫脊椎手術機器人跟腹腔鏡系統做 market sizing 跟授權模式;也以 NTU Consulting Club 的身份,幫一家跨國藥廠做 HPV 疫苗的市場進入研究。A short stint in executive search after graduating. In the same period, with a global medtech distributor's team, I sized the market and designed licence models for a spine-surgery robot and a laparoscopic system, and through the NTU Consulting Club I worked on HPV-vaccine market access for a global pharma company.

    Market sizingMarket access
  6. 2017 — 2019
    共同創辦人暨執行長Co-founder and CEO · Encorphin ↗

    2017 年 6 月到 2019 年 2 月。帶 3 人開發團隊,把門診前的問診做成候診問卷、一頁摘要跟排程流程,進了 4 家醫院、2 家診所,病人候診時間少了 67%。June 2017 to February 2019. Led a three-person dev team that turned pre-visit history-taking into an intake, a one-page summary and a scheduling workflow, live in four hospitals and two clinics, cutting patient waiting time by 67%.

    SaMDProduct discoveryencorphin.com ↗
  7. 2012 — 2019
    醫學工程學碩士(Biomedical Engineering)MS, Biomedical Engineering · National Taiwan University
    Fluorescence image of a tissue section with labelled cell nucleiThe same numbered cells imaged on day 0, 1, 2 and 3
    研究所時的雙光子顯微影像:一層一層往下掃的活體組織、組織切面的螢光影像,還有同一群細胞從第 0 天追到第 3 天。Two-photon imaging from my graduate research: a layer-by-layer scan through living tissue, a fluorescent tissue section, and the same cells tracked from day 0 to day 3.

    2017–2019:組織工程、基因轉殖(CRISPR/Cas9)。用機器學習分析 CT 跟 MRI 醫學影像,也訓練模型做單一幹細胞追蹤(single stem cell tracing),在雙光子顯微鏡下追蹤活體細胞。大學在長庚念生物科技與生醫(2012–2016)。2017–2019: tissue engineering and gene editing (CRISPR/Cas9). Machine learning on CT and MRI images, and training models for single stem-cell tracing to follow living cells under a two-photon microscope. BS in biotechnology and biomedicine at Chang Gung University (2012–2016).

    Imaging MLCT / MRICell trackingCRISPR/Cas9
這些經驗怎麼對應到角色How this maps to the role →

工作以外:Cat & Dog loverOff the clock: Cat & Dog lover

貓跟狗,我都愛。Cats or dogs? Both.

  • Two cats, an orange tabby and a brown tabby, napping side by side
  • Orange cat dozing in a sunny window
  • Orange cat sitting upright, looking at the camera
  • Orange cat looking out over the city skyline
  • Brown tabby cat asleep on a blanket
  • Grey poodle in a harness on the grass
  • Grey poodle and a white dog in a park
  • Orange cat batting at a toy
  • Orange cat held in someone's hands
  • Tabby cat rolling on its back on a cushion
  • Tabby cat upside down, staring at the camera

AIOM 示範AIOM demo

AIOM Outcome Cockpit, executive view AIOM 成果儀表板AIOM Outcome Cockpit ↗ 一個預測性維護案子每週要回答的問題:承諾的數字有沒有在動、是不是方案造成的、這週要做什麼。先看主管視角,再往下看資產層級的診斷、KPI 怎麼選、合約怎麼付款。The weekly questions of a predictive-maintenance engagement: is the promised number moving, is it the solution that moved it, and what should we do this week. Start with the executive view, then drill into asset-level diagnosis, KPI choice and how the contract pays out. 示範情境,所有數字都是虛構的示範資料,不是客戶成果。Illustrative scenario. Every number is synthetic demo data, not a client result.

聯絡Contact

在找金融或醫療的 AI 轉型、AI 策略、成果交付角色,地點在新加坡、台北或香港;也歡迎聊新創投資。歡迎直接聯絡。Looking for AI transformation, strategy or outcome-delivery roles in financial services or healthcare, in Singapore, Taipei or Hong Kong. Happy to talk startup investing too. Get in touch directly.

Email
[email protected]
WhatsApp
+65 9351 0316
地點Based in
Singapore · Taipei